Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3031 in Thyroid Eye Disease
NCT07622368Phase 1Recruiting
- Sponsor
- Innovent Biologics
- Start
- Jun 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IBI3031 in thyroid eye disease (TED) (16 arms), sponsored by Innovent Biologics. Primary endpoints: Adverse Events, Treatment-Emergent Adverse Events and 12 more. Started Jun 2026; status: recruiting.
02
Drugs
IBI3031
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT07622368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07622368.